

Resource Summary Report

Generated by [ASWG](#) on Aug 4, 2026

Pharmacology

RRID:SCR_009017

Type: Tool

Proper Citation

Pharmacology (RRID:SCR_009017)

Resource Information

URL: <http://en.wikibooks.org/wiki/Pharmacology>

Proper Citation: Pharmacology (RRID:SCR_009017)

Description: Pharmacology is a wikibook covering topics within pharmacology and pharmaceutical sciences.

Synonyms: Pharmacology (wikibook)

Resource Type: narrative resource, data or information resource, book, wiki

Resource Name: Pharmacology

Resource ID: SCR_009017

Alternate IDs: nlx_152817

Record Creation Time: 20220129T080250+0000

Record Last Update: 20260804T043411+0000

Ratings and Alerts

No rating or validation information has been found for Pharmacology.

No alerts have been found for Pharmacology.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 142 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Thomas O, et al. (2026) GLP-1 agonist-associated presentations to unscheduled care: An opportunistic pilot study. *British journal of clinical pharmacology*, 92(1), 312.

Sarömba JA, et al. (2025) Solanidine-derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients. *British journal of clinical pharmacology*, 91(6), 1842.

Yeung SA, et al. (2025) The pharmacokinetics of brensocatic in participants with renal impairment following a single oral administration. *British journal of clinical pharmacology*, 91(4), 1191.

Luo R, et al. (2025) Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants. *British journal of clinical pharmacology*, 91(7), 2070.

Bhattacharya CS, et al. (2025) The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone. *British journal of clinical pharmacology*, 91(7), 1937.

Bouazza N, et al. (2025) Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity. *British journal of clinical pharmacology*, 91(10), 2854.

Yao T, et al. (2025) Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B-cell malignancies. *British journal of clinical pharmacology*, 91(7), 2008.

Ogasawara A, et al. (2025) Physiologically based pharmacokinetic modelling to predict potential drug-drug interactions of dersimelagon (MT-7117). *British journal of clinical pharmacology*, 91(2), 451.

Wang Y, et al. (2025) Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase-1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study. *British journal of clinical pharmacology*, 91(8), 2262.

Kew BM, et al. (2025) Investigation of a broad-spectrum micronutrient formulation as a possible precipitant of pharmacokinetic micronutrient-drug interactions. *British journal of clinical pharmacology*, 91(7), 1987.

Dong Z, et al. (2024) Pharmacokinetics and pharmacodynamics of the factor XIa-inhibiting antibody osocimab in healthy male East Asian volunteers: Results from two phase 1 studies. *Pharmacology research & perspectives*, 12(5), e70012.

Richardson JC, et al. (2024) The hydroxycarboxylic acid receptor HCA2 is required for the protective effect of ketogenic diet in epilepsy. *Pharmacology research & perspectives*, 12(6), e70026.

Yoshijima C, et al. (2024) Evaluation of intra- and inter-individual variations in plasma belimumab concentrations in adult patients with systemic lupus erythematosus. *Pharmacology research & perspectives*, 12(4), e1255.

Iversen DB, et al. (2024) Dicloxacillin is an inducer of intestinal P-glycoprotein but neither dicloxacillin nor flucloxacillin increases the risk of stroke/systemic embolism in direct oral anticoagulant users. *British journal of clinical pharmacology*, 90(12), 3252.

Xu D, et al. (2024) Pharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans. *Pharmacology research & perspectives*, 12(5), e70006.

Érszegi A, et al. (2024) Not first-line antihypertensive agents, but still effective-The efficacy and safety of imidazoline receptor agonists: A network meta-analysis. *Pharmacology research & perspectives*, 12(3), e1215.

Tykvartova T, et al. (2024) The impact of phosphodiesterase-5 inhibition or angiotensin-converting enzyme inhibition on right and left ventricular remodeling in heart failure due to chronic volume overload. *Pharmacology research & perspectives*, 12(1), e1172.

Chen J, et al. (2024) An open-label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people. *Pharmacology research & perspectives*, 12(4), e1252.

Parkinson J, et al. (2024) The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses. *Pharmacology research & perspectives*, 12(2), e1184.

Holdt-Caspersen NS, et al. (2024) Adherence to newer second-line oral antidiabetic drugs among people with type 2 diabetes-A systematic review. *Pharmacology research & perspectives*, 12(2), e1185.